Vijaya Diagnostic Centre Limited announced the outcomes of its Board Meeting held on May 07, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. A final dividend of ₹2 per equity share, representing 200% on a face value of ₹1, has been recommended for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The Board also noted the decision of Dr. D. Nageshwar Reddy not to seek re-appointment for a second term as an Independent Director, with his current term concluding on May 25, 2026, due to professional commitments. M/s. Santhosh & Associates have been re-appointed as the Cost Auditors for the Financial Year 2026-27. Furthermore, the company approved the grant of 1,79,500 Employee Stock Options (ESOPs) under the "VDCL Employee Stock Option Plan 2018" at an exercise price of ₹784 per option. The Board also approved the acquisition of MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP, a wholly-owned subsidiary, for approximately ₹4.20 Crore. This acquisition is expected to be completed within 3 months and aims to foster growth opportunities in line with the company's strategic direction. The Board Meeting commenced at 05:00 P.M. and concluded at 06:45 P.M. IST.
